Celldex Therapeutics, Inc.
(NASDAQ : CLDX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.00%105.161.1%$1271.42m
GILDGilead Sciences, Inc.
-0.11%72.740.9%$640.88m
AMGNAmgen Inc.
0.44%170.711.1%$480.05m
REGNRegeneron Pharmaceuticals, Inc.
1.03%391.532.7%$362.79m
BIIBBiogen Inc.
-0.28%308.941.2%$348.83m
ALXNAlexion Pharmaceuticals, Inc.
0.56%108.211.9%$268.15m
VRTXVertex Pharmaceuticals Incorporated
0.09%147.171.9%$232.93m
ALNYAlnylam Pharmaceuticals, Inc
1.18%133.8910.0%$195.44m
INCYIncyte Corporation
-0.29%98.712.5%$178.72m
NKTRNektar Therapeutics
-2.49%48.516.1%$172.18m
ILMNIllumina, Inc.
-0.10%215.133.5%$154.37m
JUNOJuno Therapeutics, Inc.
2.14%61.6213.5%$140.57m
AAgilent Technologies, Inc.
0.58%69.091.5%$132.43m
SRPTSarepta Therapeutics, Inc.
0.50%56.5016.8%$116.20m
BLUEBluebird Bio, Inc.
0.96%168.8017.2%$115.52m

Company Profile

Celldex Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes therapeutic antibodies, antibody drug conjugates, vaccines, and immune system modulators. The company's drug candidates include Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, and Rintega. Celldex Therapeutics was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.